BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease (BENEFIT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00123916 |
|
Recruitment Status :
Completed
First Posted : July 26, 2005
Last Update Posted : March 3, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC).
The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chagas Disease Trypanosomiasis Heart Disease | Drug: Benznidazole Drug: Placebo | Phase 3 |
A randomized double-blind controlled clinical trial investigating the role of benznidazole in patients with chronic Chagas' heart disease.
Chagas disease has 3 phases: acute, undetermined and chronic phases. There are no clinical trials up to date that have investigated the use of antiparasitic drugs in patients that are in the chronic phase.
This study will evaluate the efficacy and safety of benznidazole (an antiparasitic drug) in patients with chronic Chagas' heart disease. Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). It will be developed in 49 study centres in Argentina, Bolivia,Brazil,Colombia, and El Salvador - countries with high incidence of Chagas Disease.
The Pilot study is evaluating if benznidazole is effective in producing parasitic cure (PCR negativization or reducing parasitic load) in chronic Chagas Disease as well as assessing the feasibility of conducting a large trial in chronic Chagas Disease in South America.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 2854 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial |
| Study Start Date : | November 2004 |
| Actual Primary Completion Date : | July 2015 |
| Actual Study Completion Date : | August 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Benznidazole
40 - 80 days (according to body weight) treatment with benznidazol
|
Drug: Benznidazole
Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
Other Name: Rochagan/LaFepe |
|
Placebo Comparator: Placebo
40 - 80 days (according to body weight) treatment with matching placebo
|
Drug: Placebo
a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
Other Name: Rochagan/LaFepe |
- Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant. [ Time Frame: through study completion, an average of 5 years ]Composite cardiovascular outcome,
- New development of any of the following echo changes, segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction >5%, increase in LVDD> 5 mm compared to baseline. [ Time Frame: through study completion, an average of 5 years ]
- New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc). [ Time Frame: through study completion, an average of 5 years ]
- Progression of NYHA functional class by at least one category [ Time Frame: through study completion, an average of 5 years ]
- New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.) [ Time Frame: through study completion, an average of 5 years ]
- Progression of New York Heart Association (NYHA) functional class by at least one category [ Time Frame: through study completion, an average of 5 years ]
- Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment [ Time Frame: through study completion, an average of 5 years ]
- Determination of the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR. [ Time Frame: through study completion, an average of 5 years ]Polymerase Chain Reaction study on patient's blood samples and report negativization at the end of treatment, 2Y and final visit.
- Safety and tolerability of benznidazole [ Time Frame: through study completion, an average of 5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Consenting patients (between 18 and 75 years of age) with serological evidence of Chagas infection (any combination of 2 positive tests) and that have one or more of the following:
- Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left anterior or posterior fascicular block; ventricular premature beat; first degree atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);
- Abnormal ECG (Mobitz type II, advanced or third degree AV block);
- Increased cardiothoracic ratio (> 0.50);
- Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;
- Evidence of regional wall motion abnormality or reduced global left ventricular systolic function or increased left ventricular and diastolic diameter on 2D-Echo.
Exclusion Criteria:
Patients will be excluded if having:
- NYHA heart failure class IV or decompensated heart failure
- Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated cardiomyopathy
- Previous treatment with antitrypanosomal agents or an accepted indication for antiparasitic therapy
- Inability to comply with follow-up visits
- History of severe alcohol abuse within 2 years
- Known chronic renal or hepatic insufficiency or hepatic insufficiency
- Pregnancy or breast feeding
- Megaesophagus with swallowing impairment
- Other severe disease significantly curtailing life expectancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00123916
Show 47 study locations
| Study Chair: | Carlos Morillo, MD | Population Health Research Institute - McMaster University | |
| Study Chair: | Jose Antonio Marin-Neto, MD, PhD | University of Sao Paulo | |
| Study Chair: | Salim Yusuf, MD, DPh | Population Health Research Institute - McMaster University | |
| Principal Investigator: | Sergio Sosa-Estani, MD, PhD | Argentina National Coordinator - CenDIE, Argentina | |
| Principal Investigator: | Fernando Rosas, M.D. | Fundacion Clinica Shaio, Bogota, Colombia |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Salim Yusuf's office, Principal Co-Investigator, Population Health Research Institute |
| ClinicalTrials.gov Identifier: | NCT00123916 |
| Other Study ID Numbers: |
BEN01 CONEP-11394 ( Other Identifier: Comissão Nacional de Ética em Pesquisa (CONEP) ) |
| First Posted: | July 26, 2005 Key Record Dates |
| Last Update Posted: | March 3, 2020 |
| Last Verified: | February 2020 |
|
Chagas Disease Trypanosomiasis Benznidazole Chronic Heart disease Trypanosoma Cruzi |
|
Chagas Disease Trypanosomiasis Heart Diseases Cardiovascular Diseases Euglenozoa Infections Protozoan Infections Parasitic Diseases Infections Vector Borne Diseases |
Benzonidazole Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Trypanocidal Agents Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents |